Lite Strategy (LITS) Operating Interest Expenses (2011)
Lite Strategy (LITS) posted Operating Interest Expenses of $9000.0 for Q4 2011, down 97.73% on a QoQ basis from $397000.0 in Q3 2011.
Powered by 
Analysis
Lite Strategy (LITS) Operating Interest Expenses (2011) Analysis & Trends
Lite Strategy has reported Operating Interest Expenses for 1 years, with the latest figure at $9000.0 in Q4 2011.
- On a quarterly basis, Operating Interest Expenses changed N/A year-over-year to $9000.0 in Q4 2011; TTM through Jun 2012 was $406000.0, a N/A change from a year earlier, with the FY2012 full-year figure at $406000.0, changed N/A from the prior year.
- Operating Interest Expenses was $9000.0 for Q4 2011 at Lite Strategy, down from $397000.0 in the prior quarter.
- The five-year high for Operating Interest Expenses was $397000.0 in Q3 2011, with the low at $9000.0 in Q4 2011.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Interest Exp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | - |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | - |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | - |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | - |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | - |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | - |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | - |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | - |
| 10 | Lite Strategy | 38.03 Mn | 30.49 Mn | - | - |